Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Want to cut your energy bills? Here’s how five experts are doing it 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
SAN DIEGO, March 07, 2017 -- Retrophin, Inc. (Nasdaq:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Barclays Global Healthcare Conference in Miami on Wednesday, March 15, 2017 at 2:05 p.m. ET.
A live webcast of the presentation will be available at http://ir.retrophin.com/events.cfm and an archived replay will be accessible for at least 30 days.
About Retrophin
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company’s approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Thiola®, Cholbam® and Chenodal®.
Contact: Chris Cline, CFA Senior Director, Investor Relations 646-564-3680 [email protected]
